GlassScriptPhysician profile
Ronald Lau
NPI 1558466623
$3,525.80
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $846 · 2020: $1,113 · 2021: $734 · 2022: $503 · 2023: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $330.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $783.86 | 2019-2023 | Farxiga |
| Pfizer INC. | $350.29 | 2019-2022 | |
| Esperion Therapeutics, INC. | $314.20 | 2020-2022 | |
| Novo Nordisk INC | $304.77 | 2019-2023 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $265.24 | 2019-2021 | |
| Abbvie INC. | $262.09 | 2021-2023 | |
| Amarin Pharma, INC. | $249.97 | 2020-2022 | |
| Allergan, INC. | $232.79 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.17 | 2020-2023 | Jardiance |
| Lilly USA, LLC | $147.62 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $96.91 | 2021 | |
| Merck Sharp & Dohme LLC | $70.96 | 2019-2020 | |
| Eisai INC. | $67.70 | 2019-2020 | |
| Glaxosmithkline, LLC. | $41.99 | 2020-2023 | Trelegy Ellipta, Shingrix |
| Amgen INC. | $28.14 | 2022-2023 | Otezla, Repatha |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $24.64 | 2022 | |
| Sanofi-Aventis U.S. LLC | $24.49 | 2019-2020 | |
| Exact Sciences Corporation | $21.30 | 2023 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $20.43 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.54 | 2019 | |
| Cequr Corporation | $14.21 | 2022 | |
| Sanofi Pasteur INC. | $13.69 | 2019 | |
| Daiichi Sankyo INC. | $13.36 | 2019 | |
| Endo Pharmaceuticals INC. | $12.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Lau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.